ReviewScience progress2010
Mesenchymal stem cells as a platform for gene therapy protocols.
Review in Science progress, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.Stem cells (Dayton, Ohio) · 2021Article
- The use of stem cells in aesthetic dermatology and plastic surgery procedures. A compact review of experimental and clinical applications.Postepy dermatologii i alergologii · 2017Article
- Foxp3-modified bone marrow mesenchymal stem cells promotes liver allograft tolerance through the generation of regulatory T cells in rats.Journal of translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) are considered as the adult stem cells with the greatest therapeutic potential, due to characteristics such as plasticity, intrinsic tropism towards lesions, paracrine activity, and immunosuppressive activity. This potential may be optimised by transforming them with genes which will improve their therapeutic ability or are therapeutic by themselves. This review presents a summary of the main types of viral or plasmid vectors used to transform therapeutic MSCs and their use in different pathologies. Although this strategy holds great promise, results are still heterogeneous, showing that more studies are needed to optimise gene transfer methods and models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.